Tixagevimab–cilgavimab are effective for treatment of early COVID-19 among outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. We aimed to retrospectively evaluate the hospital stay (expressed in days), prognosis, and negativity rate for COVID-19 after treatment with tixagevimab–cilgavimab. We enrolled 42 patients who were nasal swab positive for SARS-CoV-2 (antigenic and molecular), both vaccinated and not vaccinated for COVID-19, hospitalized at the first division of the Cotugno Hospital in Naples and who received intramuscular single dose of tixagevimab-cilgavimab (300 mg / 300 mg). All patients candidates for tixagevimab-cilgavimab had immunocompromised immune system either for chronic degenerative disorders (Group A: 27 patients) or onco-hematological diseases (Group B: 15patients). Patients enrolled in group A came to our observation after 10 days from the detection of positivity to COVID-19 unlike the other types of patients enrolled in this study. The mean stay in hospital of patients in Group A was 21±5 days vs 25±5 days in Group B. Twenty patients resulted negative after a median of hospitalization stay of 16 days (IQR: 18-15.25), of them 5 (25%) patients belonged to group B. Therefore, patients with active hematological malignancy had the lower negativization rate.

Background: Sepsis still represents a major public health issue worldwide, and immune system plays a main role during infections and therefore its activity is mandatory to resolve this clinical condition In this report we aimed to retrospectively verify in real life setting the possible usefulness of Pentameric IgM plus antibiotic in recovering patients with sepsis after major abdominal surgery Materials/methods: We reviewed, from January 2013 until December 2018, all adult patients admitted in ICU for Sepsis or Septic shock (2) after major abdominal surgery. Among these patients, were identified those that according to legal indication and licence in Italy, were treated with Pentameric IgM plus antibiotic (Group A) or with antibiotic alone (Group B). We analysed the following parameters were evaluated: Blood gas analysis, Lactate, CRP, Procalcitonin, Endotoxin activity, Liver and Renal Function, Coagulation, Blood Cell count at different time points (Every 48 hrs for at least 7 days. Differences between groups have been analysed by Fisher’s exact test or Chi square test for categorical variables. Mann–Whitney U test or Kruskal–Wallis test have instead been performed to compare continuous variables. Univariate and Multivariate analysis were also performed Results: Over a period of 30 months 24 patients were enrolled in Group A and 20 patients in Group B. In those subjects no statistical differences have been found in terms of bacterial or fungal infection isolates, when detected in a blood culture test, or in inflammatory index, SOFA score, lactate levels and mortality rate. A 48hrs response was statistically more frequent in Group B than in Group A, while no differences were found in the other clinical and laboratory evaluation. Conclusions: Based on our results, the use of pentameric IgM do not seem to give any clinical advantage in sepsis after to major abdominal surgery.